Skip to content

An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518698-32-00
Acronym
IP-CT-001
Enrollment
36
Registered
2024-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound healing

Interventions

None listed

Sponsors

Ilya Pharma AB (publ)
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026